With PhII fail, Redx Pharma scraps monotherapy biliary cancer development for lead program

Katherine Lewin

News Reporter

UK biotech Redx Pharma’s lead drug has failed a Phase II study for biliary tract cancer, and the results are “not sufficient” to continue development …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With PhII fail, Redx Pharma scraps monotherapy biliary cancer development for lead program

Katherine Lewin

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Trump blog: Top HHS spokesperson resigns within weeks of being sworn in

Novo Nordisk signs $354M partnership with AI-guided biotech for ‘risky’ new metabolic mechanisms

ICER finds GSK inhalers offer advantages over generic competitors

After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another

Protagonist, Takeda's profit sharing deal under spotlight after Phase 3 blood disorder trial win

The perfect storm: Why everything is in place for 2025 to be the year of GxP AI

With PhII fail, Redx Phar­ma scraps monother­a­py bil­iary can­cer de­vel­op­ment for lead pro­gram

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

With PhII fail, Redx Pharma scraps monotherapy biliary cancer development for lead program